Corbus Pharmaceuticals (CRBP) Stock Forecast, Price & News

Corbus Pharmaceuticals (NASDAQ:CRBP) Frequently Asked Questions

Is Corbus Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Corbus Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Corbus Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in CRBP, but not buy additional shares or sell existing shares.
View analyst ratings for Corbus Pharmaceuticals or view top-rated stocks.

When is Corbus Pharmaceuticals' next earnings date?

Corbus Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, August 11th 2022.
View our earnings forecast for Corbus Pharmaceuticals.

How were Corbus Pharmaceuticals' earnings last quarter?

Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) issued its earnings results on Tuesday, May, 10th. The biopharmaceutical company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.09) by $0.01. Corbus Pharmaceuticals had a negative net margin of 2,856.56% and a negative trailing twelve-month return on equity of 52.32%.
View Corbus Pharmaceuticals' earnings history.

What price target have analysts set for CRBP?

3 Wall Street analysts have issued 12-month price targets for Corbus Pharmaceuticals' shares. Their forecasts range from $2.00 to $3.00. On average, they expect Corbus Pharmaceuticals' stock price to reach $2.50 in the next twelve months. This suggests a possible upside of 1,066.6% from the stock's current price.
View analysts' price targets for Corbus Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are Corbus Pharmaceuticals' key executives?

Corbus Pharmaceuticals' management team includes the following people:

• Dr. Yuval Cohen Ph.D., CEO & Director (Age 47, Pay $846.92k)
• Mr. Sean F. Moran CPA, M.B.A., CPA, MBA, Chief Financial Officer (Age 64, Pay $542k)
• Mr. Craig Stuart Millian M.B.A., Chief Operating Officer (Age 53, Pay $542k)
• Dr. Rachael Brake Ph.D., Chief Scientific Officer (Age 50)
• Ted Jenkins, Sr. Director of Investor Relations & Corp. Communications
• Ms. Lindsey Smith, Head of Corp. Communications & Patient Advocacy
• Ms. Christina Bertsch, Head of HR
• Scott Constantine, Sr. Director & Head of Clinical Operations

Who are some of Corbus Pharmaceuticals' key competitors?

Some companies that are related to Corbus Pharmaceuticals include NervGen Pharma (NGENF), Xynomic Pharmaceuticals (XYNO), Anixa Biosciences (ANIX), Inozyme Pharma (INZY), Otonomy (OTIC), NextCure (NXTC), 9 Meters Biopharma (NMTR), Ardelyx (ARDX), Vascular Biogenics (VBLT), Xilio Therapeutics (XLO), Fortress Biotech (FBIO), DURECT (DRRX), Evelo Biosciences (EVLO), Daré Bioscience (DARE) and NRx Pharmaceuticals (NRXP).
View all of CRBP's competitors.

What other stocks do shareholders of Corbus Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Corbus Pharmaceuticals investors own include Visa (V), HP (HPQ), Fortive (FTV), Lowe's Companies (LOW), Sorrento Therapeutics (SRNE), Exelixis (EXEL), Matinas BioPharma (MTNB), (CGC), Inovio Pharmaceuticals (INO) and KushCo (KSHB).

What is Corbus Pharmaceuticals' stock symbol?

Corbus Pharmaceuticals trades on the NASDAQ under the ticker symbol "CRBP."

Who are Corbus Pharmaceuticals' major shareholders?

Corbus Pharmaceuticals' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (3.43%), Mirae Asset Global Investments Co. Ltd. (3.00%), Renaissance Technologies LLC (0.92%), Pinnacle Associates Ltd. (0.73%), GSA Capital Partners LLP (0.41%) and Davy Global Fund Management Ltd (0.35%). Company insiders that own Corbus Pharmaceuticals stock include Craig Stuart Millian, Sean F Moran and Yuval Cohen.
View institutional ownership trends for Corbus Pharmaceuticals.

Which major investors are selling Corbus Pharmaceuticals stock?

CRBP stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Mirae Asset Global Investments Co. Ltd., Simplex Trading LLC, Pinnacle Associates Ltd., and Group One Trading L.P..
View insider buying and selling activity for Corbus Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying Corbus Pharmaceuticals stock?

CRBP stock was bought by a variety of institutional investors in the last quarter, including Renaissance Technologies LLC, GSA Capital Partners LLP, and Davy Global Fund Management Ltd. Company insiders that have bought Corbus Pharmaceuticals stock in the last two years include Craig Stuart Millian, Sean F Moran, and Yuval Cohen.
View insider buying and selling activity for Corbus Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of Corbus Pharmaceuticals?

Shares of CRBP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Corbus Pharmaceuticals' stock price today?

One share of CRBP stock can currently be purchased for approximately $0.21.

How much money does Corbus Pharmaceuticals make?

Corbus Pharmaceuticals has a market capitalization of $26.84 million and generates $880 thousand in revenue each year. The biopharmaceutical company earns $-45.64 million in net income (profit) each year or ($0.33) on an earnings per share basis.

How many employees does Corbus Pharmaceuticals have?

Corbus Pharmaceuticals employs 41 workers across the globe.

What is Corbus Pharmaceuticals' official website?

The official website for Corbus Pharmaceuticals is www.corbuspharma.com.

How can I contact Corbus Pharmaceuticals?

Corbus Pharmaceuticals' mailing address is 500 River Ridge Drive, Norwood MA, 02062. The biopharmaceutical company can be reached via phone at (617) 963-0100, via email at [email protected], or via fax at 617-663-6085.